Treatment for glioblastoma (GBM)
Intended for US audiences only.

The power to
PUT GBM
ON PAUSE

and PUT LIFE ON PLAY

Marcia is an Optune user

Scroll

In people with newly diagnosed GBM

Proven to extend survival and maintain
quality of life

A large clinical study showed that adding Optune to chemotherapy* provided the greatest opportunity to live longer compared to chemotherapy alone at 5 years.

People in the study were also able to maintain their mental, emotional, and physical well-being longer than those on chemotherapy alone.

Nearly half of people on Optune plus chemotherapy were alive at 2 years compared with 31% of people on chemotherapy alone.

Learn more

"I'm still working full time at a desk job and maintain some of my hobbies, like woodworking. So far, it's been awesome."
—Brian, an Optune user

Learn more about Brian

Optune delivers Tumor Treating Fields (TTFields) to the location of the tumor without increasing chemotherapy-related side effects.

Optune is a wearable, portable
FDA-approved treatment for GBM.

Explore Optune

There are more than 700 certified treatment centers
in the United States where a doctor will prescribe
Optune for you.

Find an Optune doctor

I agree with the Terms and Conditions

References:
  1. Optune [Instructions for Use]. Novocure 2016.
  2. Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA Oncology. 2­0­1­7;3­1­8­(­2­3­)­:­2­3­0­6-23­1­6
  3. Taphoorn M, Dirven L, Kanner A, et al. Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma:
    a secondary analysis of a randomized clinical trial. JAMA Oncology. doi:1­0­.­1­0­0­1/jamaoncol.2­0­1­7­.­5­0­8­2. Published online Feburary 1, 2018.
  4. Optune Fact Sheet. https://www.novocure.com/wp-content/uploads/2016/08/OPT-539_Optune-Fact-Sheet_062016-3.pdf. Novocure; 2017.
  5. Novocure Data on File, 115.1.

OPT-1605

What is Optune® approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.

Newly diagnosed GBM

If you have newly diagnosed GBM, Optune is used together with a chemotherapy called temozolomide (TMZ) if:

Recurrent GBM

If your tumor has come back, Optune can be used alone as an alternative to standard medical therapy if:

Who should not use Optune?

Optune is not for everyone. Talk to your doctor if you have:

Do not use Optune if you are pregnant or are planning to become pregnant. It is not known if Optune is safe or effective during pregnancy.

What should I know before using Optune?

Optune should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure™, the maker of Optune.

What are the possible side effects of Optune?

Most common side effects of Optune when used together with chemotherapy (temozolomide, or TMZ) were low blood platelet count, nausea, constipation, vomiting, tiredness, scalp irritation from the device, headache, seizure, and depression.

The most common side effects when using Optune alone were scalp irritation (redness and itchiness) and headache. Other side effects were malaise, muscle twitching, fall and skin ulcers.

Talk to your doctor if you have any of these side effects or questions.


Please click here to see the Optune Instructions for Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

What is Optune approved to treat?

Optune is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 years of age or older.